Heterozygote advantage at HLA class I and II loci and reduced risk of colorectal cancer.
Tsai YY, Qu C, Bonner JD, Sanz-Pamplona R, Lindsey SS, Melas M, McDonnell KJ, Idos GE, Walker CP, Tsang KK, Da Silva DM, Moratalla-Navarro F, Maoz A, Rennert HS, Kast WM, Greenson JK, Moreno V, Rennert G, Gruber SB, Schmit SL.
Tsai YY, et al. Among authors: gruber sb.
Front Immunol. 2023 Oct 24;14:1268117. doi: 10.3389/fimmu.2023.1268117. eCollection 2023.
Front Immunol. 2023.
PMID: 37942321
Free PMC article.